Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database - 11/08/23
, Charbel Mouawad b, Delphine Gueguen b, Benoit Thomé c, Maryse Lapeyre-Mestre d, Thomas Walter aHighlights |
• | The mean overall cost per person per month was €2892 in patients with carcinoid syndrome. |
• | The first year following diagnosis and the year preceding death are the two periods representing the highest costs for carcinoid syndrome care in France. |
• | The two most costly expenditure items were drugs and hospital stays. |
• | Estimating direct and indirect costs of carcinoid syndrome are important drivers of public health decision making. |
Abstract |
Objectives |
Carcinoid syndrome (CS) develops in approximately 20% of patients with neuroendocrine tumours (NET). This study described healthcare resource utilization and its associated costs among patients with NET and CS, using the French national health care data system.
Methods |
Patients were included if they had a hospital stay associated with the code E34.0 "CS" and at least one delivery of a somatostatin analogue (SSA) between 01/01/2012 and 31/12/2016. The end of the analysis was either 31/12/2017 or the date of death, whichever occurred first. Mean overall costs were described by item of expenditure and by periods.
Results |
646 patients were included: 64yo, 55% men, 64% and 15% had NET from the small-intestine or lung, respectively. Among them, 309 patients were incident and 271 died during the study period. Mean overall cost per person per month (PPPM) was €2,892: €3,273 for the first year following diagnosis, €2,574 in “middle-years” and €5,039 within the year preceding death. The two most costly expenditure items were drugs (€1,695 PPPM) and hospital stays (€870 PPPM).
Conclusion |
The first year following diagnosis and the year preceding death are the two periods representing the highest costs for CS care in France. Successful disease management may contribute to lower costs in the intermediate period.
Le texte complet de cet article est disponible en PDF.Keywords : Carcinoid syndrome, Resources, Healthcare expenditure, Cost, Neuroendocrine tumours
Plan
Vol 47 - N° 7
Article 102177- août 2023 Retour au numéro
Article précédent
- Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer
- Safa Can Efil, Gunes Guner, Deniz Can Guven, Burcu Celikten, Elvin Celebiyev, Hakan Taban, Aytekin Akyol, Aynur Isik, Sadettin Kilickap, Suayib Yalcin, Omer Dizdar
- Nutrition support in pancreatic cancer: An expert statement on practical implementation of French guidelines
- Julien Taieb, Raëf Abdallah, Ronan Thibault, Patrick Pessaux, Pascal Artru, Timothée Marchal, Cindy Neuzillet
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?